1647

Docket No.: NIH173.001C1 **Customer No.: 20,995**

AMENDMENT / RESPONSE TRANSMITTAL

Applicant	:	Wang et al.
App. No.	:	10/099,782
Filed	:	March 14, 2002
For	:	UTILIZATION OF FPRL1 AS A FUNCTIONAL RECEPTOR BY SERUM AMYLOID A (SAA)
Examiner	:	Turner, Sharon L.
Art Unit	:	1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

December 4, 2003
(Date)

Nancy W. Vensko, Reg. No. 36,298

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-identified application are the following enclosures:

(X) Response to Restriction Requirement in 6 pages.

The fee has been calculated as shown below:

FEE CALCULATION				
FEE TYPE		**FEE CODE**	**CALCULATION**	**TOTAL**
Total Claims	28 - 28 = 0	1202 ($18)	0 x 18 =	$0
Independent Claims	8 - 8 = 0	1201 ($86)	0 x 86 =	$0
Multiple Claim		1203 ($290)		$0
			TOTAL FEE DUE	**$0**

(X) Return prepaid postcard.

(X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Nancy W. Vensko
Registration No. 36,298
Attorney of Record
Customer No. 20,995
(805) 547-5580

O:\DOCS\NWV\NWV-9344.DOC:vb 120203

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Wang, et al.
Appl. No.	:	10/099,782
Filed	:	March 14, 2002
For	:	UTILIZATION OF FPRL1 AS A FUNCTIONAL RECEPTOR BY SERUM AMYLOID A (SAA)
Examiner	:	Turner, Sharon L.
Group Art Unit	:	1647

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement mailed November 4, 2003 in the above-identified application, Applicant responds as follows:

Restriction to one of the following groups was required under 35 U.S.C. 121:

I. Claim 1 drawn to an isolated complex, classified for example in class 530, subclass 350.

II. Claim 2 drawn to a polypeptide fragment of SAA that inhibits assembly, classified for example in class 530, subclass 300.

III. Claim 3 drawn to a nucleic acid encoding the polypeptide of claim 2, classified for example in class 536, subclass 23.1.

IV. Claim 4 drawn to a polypeptide fragment of FPRL1 that inhibits assembly, classified for example in class 530, subclass 300.

V. Claim 5 drawn to a nucleic acid encoding the polypeptide of claim 4 classified for example in class 536, subclass 23.1.

VI. Claim 6 drawn to a method of inhibiting assembly of an SAA/FPRL1 complex comprising administration of the peptide of claim 2, classified for example in class 435, subclass 7.1.

VII. Claim 6 drawn to a method of inhibiting assembly of an SAA/FPRL1 complex comprising administration of the peptide of claim 4, classified for example in class 435, subclass 7.1.

VIII. Claim 7 drawn to a method of identifying an agent that modulates assembly of SAA/FPRL1 comprising contacting a support, classified for example in class 435, subclass 7.1.

IX. Claim 8 in part drawn to a polypeptide fragment of SAA identified by the method of claim 7 classified for example in class 530, subclass 300.

X. Claim 8 in part drawn to a polypeptide fragment of FPRL1 identified by the method of claim 7 classified for example in class 530, subclass 350.

XI. Claim 9 in part drawn to a peptidomimetic that resembles the polypeptide of claim 8 to the extent of SAA, classified for example in class 530, subclass 300.

XII. Claim 9 in part drawn to a peptidomimetic that resembles the polypeptide of claim 8 to the extent of FPRL, classified for example in class 530, subclass 300.

XIII. Claim 10 in part, drawn to a nucleic acid encoding at least a portion of SAA identified by the method of claim 7 classified for example in class 536, subclass 23.1.

XIV. Claim 10 in part, drawn to a nucleic acid encoding at least a portion of FPRL1 identified by the method of claim 7 classified for example in class 536, subclass 23.1.

XV. Claim 11 in part drawn to a method of modulating a cellular response in a subject comprising administration of a sequence that corresponds to SAA classified for example in class 424, subclass 184.1.

XVI. Claim 11 in part drawn to a method of modulating a cellular response in a subject comprising administration of a sequence that corresponds to FPRL1 classified for example in class 424, subclass 184.1.

XVII. Claim 12 drawn to a method of modulating a cellular response in a subject comprising administration of an acidic amino acid replaced sequence of SAA, classified for example in class 424, subclass 184.1.

XVIII. Claim 13 drawn to a method of modulating a cellular response in a subject comprising administration of a basic amino acid replaced sequence of SAA, classified for example in class 424, subclass 184. 1.

XIX. Claim 14 drawn to a method of modulating a cellular response in a subject comprising administration of a nonpolar amino acid replaced sequence of SAA, classified for example in class 424, subclass 184.1.

XX. Claim 15 drawn to a method of modulating a cellular response in a subject comprising administration of an uncharged amino acid replaced with a different uncharged amino acid of SAA, classified for example in class 424, subclass 184.1.

XXI. Claim 16 drawn to a method of modulating a cellular response in a subject comprising administration of an aromatic amino acid replaced with a different aromatic amino acid of SAA, classified for example in class 424, subclass 184.1.

XXII. Claim 17 in part drawn to a method of modulating a cellular response in a subject comprising administration of a peptide sequence that corresponds to SAA and measuring the effect of the peptide agent as a ligand that interacts with a FPRL1 receptor, classified for example in class 514, subclass 2.

XXIII. Claim 17 in part drawn to a method of modulating a cellular response in a subject comprising administration of a peptide sequence that corresponds to FPRL1 and measuring the effect of the peptide agent as a ligand that interacts with a FPRL1 receptor, classified for example in class 514, subclass 2.

XXIV. Claim 18 in part drawn to a method of modulating a cellular response in a subject comprising administration of an acidic amino acid replaced sequence of SAA and measuring the effect of the peptide agent as a ligand that interacts with a FPRL1 receptor, classified for example in class 514, subclass 2.

XXV. Claim 18 in part drawn to a method of modulating a cellular response in a subject comprising administration of an acidic amino acid replaced sequence of FPRL1 and measuring the effect of the peptide agent as a ligand that interacts with a FPRL1 receptor, classified for example in class 514, subclass 2.

XXVI. Claim 19 in part drawn to a method of modulating a cellular response in a subject comprising administration of a basic amino acid replaced sequence of SAA and measuring the effect of the peptide agent as a ligand that interacts with a FPRL1 receptor, classified for example in class 514, subclass 2.

XXVII. Claim 19 in part drawn to a method of modulating a cellular response in a subject comprising administration of a basic amino acid replaced sequence of FPRL1 and measuring the effect of the peptide agent as a ligand that interacts with a FPRL1 receptor, classified for example in class 514, subclass 2.

XXVIII. Claim 20 in part drawn to a method of modulating a cellular response in a subject comprising administration of a nonpolar amino acid replaced sequence of SAA and measuring the effect of the peptide agent as a ligand that interacts with a FPRL1 receptor, classified for example in class 514, subclass 2.

XXIX. Claim 20 in part drawn to a method of modulating a cellular response in a subject comprising administration of a nonpolar amino acid replaced sequence of FPRL1 and measuring the effect of the peptide agent as a ligand that interacts with a FPRL1 receptor, classified for example in class 514, subclass 2.

XXX. Claim 21 in part drawn to a method of modulating a cellular response in a subject comprising administration of an uncharged amino acid replaced with a different uncharged amino acid of SAA and measuring the effect of the peptide agent as a ligand that interacts with a FPRL1 receptor, classified for example in class 514, subclass 2.

XXXI. Claim 21 in part drawn to a method of modulating a cellular response in a subject comprising administration of an uncharged amino acid replaced with a different uncharged amino acid of FPRL1 and measuring the effect of the peptide agent as a ligand that interacts with a FPRL1 receptor, classified for example in class 514, subclass 2.

XXXII. Claim 22 in part drawn to a method of modulating a cellular response in a subject comprising administration of an aromatic amino acid replaced with a different aromatic amino acid of SAA and measuring the effect of the peptide agent as a ligand that interacts with a FPRL1 receptor, classified for example in class 514, subclass 2.

XXXIII. Claim 22 in part drawn to a method of modulating a cellular response in a subject comprising administration of an aromatic amino acid replaced with a different aromatic amino acid of FPRL1 and measuring the effect of the peptide agent as a ligand that interacts with a FPRL1 receptor, classified for example in class 514, subclass 2.

XXXIV. Claim 23 in part drawn to a method of making a pharmaceutical product comprising providing a peptide product comprising a peptide having a sequence corresponding to SAA, providing a cell, contacting, identifying and incorporating, classified for example in class 435, subclass 69.1.

XXXV. Claim 23 in part drawn to a method of making a pharmaceutical product comprising providing a peptide product comprising a peptide having a sequence corresponding to FPRL1, providing a cell, contacting, identifying and incorporating, classified for example in class 435, subclass 69.1.

XXXVI. Claim 24 drawn to a method of making a pharmaceutical product comprising providing a peptide product comprising a peptide having a sequence corresponding to an acidic amino acid replaced sequence of SAA, providing a cell, contacting, identifying and incorporating, classified for example in class 435, subclass 69.1.

XXXVII. Claim 25 drawn to a method of making a pharmaceutical product comprising providing a peptide product comprising a peptide having a sequence corresponding to a basic amino acid replaced sequence of SAA, providing a cell, contacting, identifying and incorporating, classified for example in class 435, subclass 69.1.

XXXVIII. Claim 26 drawn to a method of making a pharmaceutical product comprising providing a peptide product comprising a peptide having a sequence corresponding to a nonpolar amino acid replaced sequence of SAA, providing a cell, contacting, identifying and incorporating, classified for example in class 435, subclass 69.1.

XXXIX. Claim 27 drawn to a method of making a pharmaceutical product comprising providing a peptide product comprising a peptide having a sequence corresponding to a uncharged amino acid replaced with a different uncharged amino acid sequence of SAA, providing a cell, contacting, identifying and incorporating, classified for example in class 435, subclass 69.1.

XL. Claim 28 drawn to a method of making a pharmaceutical product comprising providing a peptide product comprising a peptide having a sequence corresponding to an aromatic amino acid of SAA replaced with a different aromatic amino acid, providing a cell, contacting, identifying and incorporating, classified for example in class 435, subclass 69.1.

In response to the restriction requirement, Applicant elects Group XXXIV, that is, Claim 23 in part drawn to a method of making a pharmaceutical product comprising providing a peptide product comprising a peptide having a sequence corresponding to SAA, providing a cell, contacting, identifying and incorporating.

CONCLUSION

In view of the foregoing, Applicant respectfully requests that this application be passed to issuance. If any points remain that can be resolved by telephone, the Examiner is invited to contact the undersigned at the below-given telephone number.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 12/4/03

By: _____

Nancy W. Vensko
Registration No. 36,298
Attorney of Record
Customer No. 20,995
(805) 547-5585

O:\DOCS\MXG\MXG-4090.DOC
120103